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Abstract
Thiazolidinediones (TZDs), peroxisome proliferator-activated receptor gamma (PPARγ) 
agonists, are highly effective antidiabetic drugs that are widely used to treat type 2 dia-
betes mellitus (T2DM) due to their unique beneficial actions, such as a renoprotective 
effect, amelioration of glucose homeostasis, and blood pressure lowering, that other 
antidiabetic drugs do not have. Those beneficial actions, however, are shadowed by the 
increased risks of cardiovascular adverse events, including mitochondrial dysfunction, 
oxidative stress and myocardial energy deficiency, fluid retention, congestive heart 
failure, and myocardial infarction. Except PPARγ, TZDs also have affinity to numer-
ous non-PPARγ targets in mitochondria, cytosol, and cytoplasm, including MitoNEET, 
mitochondrial pyruvate carrier, dehydrogenases involved in tricarboxylic acid cycle and 
electron transport, cytoplasmic ion channels, Na-K-pump, and other unknown enzymes. 
By binding to these targets, TZDs produce off-target effects and potentially increase car-
diotoxicity. In this chapter, we review recent studies, both experimental and clinical, on 
the myocardial adverse effects associated with TZDs and their underlying mechanisms. 
We focus our review in large part on the relationship between these myocardial adverse 
effects and PPARγ.
Keywords: thiazolidinedione, myocardial energy metabolism, mitochondria, oxidative 
stress, peroxisome proliferator-activated receptors, heart failure, myocardial infarction
1. Introduction
Thiazolidinediones (TZDs) including ciglitazone, pioglitazone, rosiglitazone, and tro-
glitazone, also known as glitazones after the prototypical drug ciglitazone, are a class of 
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heterocyclic compounds consisting of a five-membered C3NS ring. Among them, pioglitazone 
and rosiglitazone were approved for clinical use in the United States and Canada. Through 
activation of peroxisome proliferator-activated receptor gamma (PPARγ), these compounds 
improve insulin sensitivity, reduce hyperglycemia, and afford unique beneficial actions, such 
as a renoprotective effect and blood pressure lowering that other antidiabetic drugs do not 
have [1]. Therefore, they have been widely used to treat type 2 diabetes mellitus (T2DM) as 
monotherapy or in combination with other types of oral antidiabetic agents (sulfonylureas, 
metformin, and acarbose). Their original approvals were based on the ability to reduce insu-
lin resistance, increase peripheral glucose utilization, and decrease hepatic glycogen output, 
accordingly, lower blood glucose concentration [2]. TZDs provide robust improvement in 
glycemic control that is comparable to other established agents, such as metformin and the 
sulfonylureas [3, 4]. More importantly, since the progressive failure and loss of β-cells are ulti-
mately responsible for the onset and progression of T2DM, the potential of TZDs to preserve 
β-cells is an extremely desirable function in glucose-lowing medicine [5–7]. According to 
ADOPT (A diabetes Outcome Prevention Study), the rate of monotherapy failure with TZDs 
is lower than other antidiabetic agents such as metformin and glyburide [8].
The ultimate value of TZDs and any other glucose-lowing drugs should rely on not only 
the improvement of acute hyperglycemic crises and their serious consequences, but also the 
reduction of long-term complications associated with diabetes. Theoretically, reducing hyper-
glycemia over the long term should decrease the possibility of the complications, but this is 
not the case for rosiglitazone. Instead, its beneficial actions are shadowed by the increased 
risks of cardiovascular adverse events [9].
The coexistence of heart failure (HF) and T2DM is common and has a strong impact on 
clinical management and prognosis. The action of any antidiabetic therapy on cardiovascu-
lar system is particularly important because more than 70% of deaths in diabetic patients 
are from cardiovascular causes [10], and clinical courses of cardiovascular events and T2DM 
frequently progress in parallel [11, 12]. Glucose-lowering drugs, including the TZDs, have 
complex organ-specific effects on diverse biological processes that may determine the effects 
on cardiovascular events end point. Unfortunately, the potential for unexpected cardiovascu-
lar side effects when rosiglitazone is administered to patients was not fully assessed before 
the approval from U.S. Food and Drug Administration (FDA) in 1999 and from the European 
Medicines Evaluation Agency (EMEC) in 2000. According to over 40 clinical trials conducted 
from 1999 to 2007, rosiglitazone has been reported to increase risks of heart failure [13, 14] and 
myocardial infarction in T2DM patients [15–17]. Additionally, rosiglitazone was associated 
with a significant increase in the risk of death from cardiovascular causes that had borderline 
significance [13, 16, 18, 19]. Rosiglitazone may also worsen the clinical course in patients with 
pre-existing left ventricular dysfunction [20]. Approximately 10 years after the introduction 
of rosiglitazone, EMEC required two post-marketing studies on long-term adverse effects 
and recommended that rosiglitazone be suspended from the European market because the 
benefits no longer outweighed the risk. Similarly, pioglitazone therapy was also associated 
with an increased risk of major adverse cardiovascular events in patients with pre-diabetes 
or insulin resistance and diabetes [21]. In this chapter, we review recent studies, both experi-
mental and clinical, on the myocardial adverse effects associated with TZDs, rosiglitazone in 
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particular, and discuss their underlying mechanisms. We focus our discussion in large part on 
the relationship between these myocardial adverse effects and PPARγ.
2. On-target effects of TZDs
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription fac-
tors of nuclear hormone receptor superfamily comprising three subtypes such as PPARα, 
PPARβ/δ, and PPARγ [22]. PPARα is predominantly expressed in metabolically active tissues 
such as the adipose tissue, liver, heart, kidney and skeletal muscle [23], and mainly influences 
fatty acid metabolism and its activation lowers lipid levels [24]. PPARβ/δ is ubiquitously 
expressed with the highest levels in the intestine, colon, skin, adipose tissue, skeletal muscle 
and brain and kidney [25] and is involved in fatty acid oxidation in muscle [26]. PPARγ is 
mostly expressed in adipose tissue, but also found in the skeletal muscle, liver, kidney, colon, 
Cells Target genes Gene 
expression
On-target effects Reference
Adipocyte Acetyl-CoA synthetase ↑ ↑ triglyceride [31]
Adipocyte Adipocyte-specific fatty acid binding 
protein
↑ ↑ lipid oxidation [32]
Adipocyte Cbl-associated protein ↑ ↑ insulin sensitivity [33]
Adipocyte Fatty acid translocase ↑ ↑ fatty acid uptake [34]
Hepatocyte, β-cell Glucokinase ↑ ↑ glucose 
homeostasis
[35, 36]
Hepatocyte, β-cell Glucose transporter 2 ↑ ↑ glucose sensing [35]
Adipocyte Glucose transporter 4 ↑ ↑ glucose uptake [37]
Adipocyte Glycerol kinase ↑ ↓ free fatty acid [38, 39]
Adipocyte Insulin receptor substrate 2 ↑ ↑ insulin sensitivity [40]
Adipocyte, 
hepatocyte
Interleukin-6 ↓ ↑ insulin sensitivity [41, 42]
Adipocyte Leptin ↓ ↑ insulin sensitivity [43, 44]
Adipocyte, muscle 
cell
Lipoprotein lipase ↑ ↓ triglyceride [45, 46]
Adipocyte Perilipin ↑ ↓ free fatty acid [47, 48]
Adipocyte, 
hepatocyte
Phosphoenolpyruvate carboxykinase ↑ ↑ triglyceride
↓ lipid oxidation
[30, 32, 49]
Adipocyte, 
hepatocyte
Tumor necrosis factor-α ↓ ↑ insulin sensitivity [41]
Table 1. Selected PPARγ on-target effects of TZDs.
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intestine, pancreas, brain, immune cells, and retina and throughout the cardiovascular system 
at relatively low levels [24, 25, 27]. Activation of PPARγ causes lipogenesis, adipocyte dif-
ferentiation, and insulin sensitization and enhances glucose metabolism and also decreases 
plasma free fatty acid level [26]. Functionally, this receptor controls the expression of net-
works of genes involved in adipogenesis, lipid and glucose metabolism, inflammation and 
maintenance of metabolic homeostasis. TZDs act by activating PPARγ. When activated, 
PPARγ and retinoid X receptor (RXR) form heterodimeric complex PPARγ /RXR, which then 
binds to a specific DNA sequence element termed peroxisome proliferator response element 
(PPRE), increasing transcription of various involved genes and decreasing transcription of 
others [28, 29]. The major effects of expression and repression of the aforementioned genes 
are to increase the storage of fatty acids in adipocytes, thereby decreasing the amount of fatty 
acids present in circulation. Accordingly, cells become more dependent on the oxidation of 
carbohydrates, more specifically glucose, in order to yield energy for other cellular processes. 
Therefore, TZDs improve insulin sensitivity and reduce hyperglycemia [30]. PPARγ on-target 
effects of TZDs are summarized in Table 1.
Besides, TZDs selectively augment or partially mimic certain actions of insulin, causing a 
slowly generated hypoglycemic effect without increasing pancreatic insulin secretion in non-
insulin-dependent diabetic patients via the activation of PPARγ, which increases transcrip-
tion of certain insulin-sensitive genes [2]. Thus, the action of TZDs is often accompanied by a 
reduction in circulating concentrations of insulin, triglycerides and non-esterified fatty acids 
while the β-cell function is largely restored. The PPARγ on-target effects of TZDs, however, 
are still not completely clear.
3. Off-target effects of TZDs
Drugs exert desired and undesired effects based on their binding interactions with protein 
target(s) and off-target(s), providing evidence for its efficacy and toxicity. Many different and 
seemingly unrelated side effects have emerged during the development of TZDs, such as fatal 
hepatotoxicity, rhabdomyolysis, nephrotoxicity, multisystem organ failure, etc. In isolated 
hearts [50] or in vivo [25], rosiglitazone suppressed Jun NH2-terminal kinase and activated the adenosine monophosphate-activated protein kinase and protein kinase B (AKT) pathways, 
and these effects could not be fully blocked by a PPARγ antagonist [51]. Similarly, studies in 
the pig demonstrated rapid effects of troglitazone in the recovery of left ventricular function 
after ischemia/reperfusion injury [52, 53]. The effect of troglitazone in this model was found 
to be imparted not by the TZD moiety but by its tocopherol moiety, which does not activate 
PPARγ [53]. Together these data suggest that in addition to PPARγ-dependent (on-target) 
effects, TZDs also exert PPARγ-independent (off-target) effects.
Using [3H]pioglitazone, a structurally related iodinated photoaffinity probe, mass spectrom-
etry analysis and amino-terminal sequencing, a 17-kDa mitochondrial protein mitoNEET has 
been identified as a saturable and specific binding site for [3H]pioglitazone [54]. MitoNEET is 
broadly expressed in insulin-sensitive tissues including the liver, muscle, adipose, and heart 
[55]. MitoNEET is an integral iron-sulfur-cluster transfer protein in the outer mitochondrial 
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membrane that has been shown to inhibit mitochondrial iron transport, which may in turn 
decrease mitochondrial respiratory activity [56, 57], oxidative capacity [55] and redox-sensi-
tive signaling [58]. Overexpressing mitoNEET in adipocytes decreased the levels of reactive 
oxygen species [57]. In contrast, knocking down mitoNEET in adipocytes increased reactive 
oxygen species-induced protein damage [57].
Similarly, the mitochondrial pyruvate carrier 2 (Mpc-2) has also been identified as a direct 
mitochondrial target of the TZDs (mTOT) using photoaffinity and mass spectrometry-based 
proteomics approaches [59]. Two mTOT-binding TZDs with little effect on PPARγ (MSDC-
0160 and MSDC-0602) were shown to enhance brown adipose tissue formation and improve 
insulin sensitivity in mice, whereas the deletion of the Mpc-2/mTOT gene resulted in a loss of 
brown adipose tissue formation [59]. A phase IIb study in patients with diabetes suggested 
that MSDC-0160 may have similar glucose-lowering efficacy to pioglitazone, with prelimi-
nary hints of fewer side effects [60]. MSDC-0160 was associated with a lower level of fluid 
retention [60]. These data suggest that specifically targeting Mpc-2/mTOT may have potential 
as a therapy for diabetes, and that both on-target and off-target effects may contribute to 
efficacy of the drugs, but off-target effects potentially increase cardiotoxicity.
Pioglitazone and rosiglitazone possess a common functional core, glitazone, which is consid-
ered a privileged scaffold upon which to build a drug selective for a given target-in this case, 
PPARγ. A retrospective analysis of pioglitazone and rosiglitazone has identified numerous 
non-PPARγ proteins as high affinity binders of TZDs in the rat heart, including mitochondrial 
and cytoplasmic dehydrogenases, ion channels, modulators and enzymes involved in glucose 
homeostasis, mitochondrial energy production and synaptic transduction [61].
Defining the off-target effects of TZDs and determining whether their cardiovascular adverse 
effects are mediated through PPARγ-dependent or -independent mechanisms will be critical 
in developing new therapeutic agents. From this point of view, we discuss recent studies, 
both experimental and clinical, on the myocardial adverse effects associated with TZDs, par-
ticularly rosiglitazone and their underlying mechanisms, focusing in large part on PPARγ-
independent (off-target) mechanism in the following context.
4. Rosiglitazone causes myocardial energy deficiency and 
mitochondrial dysfunction via PPARγ-independent mechanism
Using 31P-nuclear magnetic resonance (NMR) spectroscopy, we measured intracellular 
phosphocreatine (PCr), adenosine triphosphate (ATP), and calculated free energy of ATP 
hydrolysis (ΔG
ATP
) in isolated beating hearts perfused in Langendorff mode with regular 
Krebs-Henseleit buffer containing 10 mM glucose and 0.5 mM pyruvate. At baseline, all hearts 
from cardiomyocyte-specific PPARγ deficient (PPARγ−/−) mice and their littermate control 
(PPARγ+/+) mice showed similar PCr and ATP resonance areas, and PCr/ATP ratio, indicating 
the loss of regulatory action of cardiomyocyte PPARγ on myocardial energy metabolism can 
be compensated in vivo. At the human therapeutic concentrations of 1 and 3 μM, rosiglitazone 
showed no marked effects on the resonance areas and concentrations of intracellular PCr 
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([PCr]) and ATP ([ATP]). At the supratherapeutic concentrations of 10 and 30 μM, however, 
rosiglitazone decreased myocardial [PCr], [ATP], and ΔG
ATP
 in both PPARγ−/− and PPARγ+/+ 
mice in parallel compared with their vehicle controls [62]. To confirm the results from 31P-
NMR spectroscopy, we freeze-clamped hearts from those mice at the end of each experiment 
and then measured total ATP, ADP, AMP content using HPLC and calculated energy charge. 
Consistent with the abovementioned results, total ATP content, ATP to ADP ratio and energy 
charge decreased following acute treatment with rosiglitazone at 10 and 30 μM in hearts from 
both PPARγ−/− and PPARγ+/+ mice compared with vehicle control [62].
Since mitochondrial oxidation of fatty acid and glucose is a major source of ATP in cardio-
myocytes, we measured glucose and palmitate oxidation rates in fresh tissue homogenates 
using [1-14C]-glucose and [1-14C]-palmitic acid, respectively. At the therapeutic concentrations 
of 1 and 3 μM, incubation of rosiglitazone with myocardial homogenates for 60 min did not 
change glucose and palmate oxidation rates. At the supratherapeutic concentrations of 10 
and 30 μM, however, it decreased oxidation rates of glucose and palmitate in myocardial 
homogenate from both PPARγ−/− and PPARγ+/+ mice to the same extent. Consistently, rosigli-
tazone decreased also mitochondrial respiration rate at these supratherapeutic concentrations 
in both homogenates [62].
We then determined the effects of rosiglitazone on both mitochondrial and cytosolic rate-
limiting enzymes controlling ATP synthesis. When incubated with fresh tissue homogenate 
or isolated mitochondria for 60 min, rosiglitazone at 1 and 3 μM did not affect the activi-
ties of cytosolic and mitochondrial enzymes tested as compared with vehicle treatment. At 
the supratherapeutic concentrations of 10 and 30 μM, however, rosiglitazone decreased the 
activities of myocardial mitochondrial complexes I and IV in both PPARγ−/− and PPARγ+/+ 
mice to the same extent, but did not alter the activities of other mitochondrial enzymes citrate 
synthase, creatine kinase, Complexes II, III, V and cytosolic enzymes phosphofructokinase, 
lactate dehydrogenase and glyceraldehyde 3-phosphate dehydrogenase [62]. These results 
indicate that the higher concentrations of rosiglitazone caused myocardial energy deficiency 
and mitochondrial dysfunction in the cardiomyocytes in a PPARγ-independent manner. 
Consistent with our study, Brunmair et al. reported that 10–100 μM TZDs rosiglitazone, 
troglitazone and pioglitazone inhibited mitochondrial complex I activity, respiratory con-
trol and glucose oxidation in the rat liver and skeletal muscles [63]; Rachek et al. found that 
troglitazone induced mitochondrial dysfunction and cell death in human hepatocytes [64]; 
results from Scatena et al. also suggested that TZDs induced a non-PPARγ-mediated effect: 
mitochondrial respiratory chain dysfunction [65].
The PPARγ-independence of rosiglitazone-induced energy deficiency and mitochondrial 
dysfunction are also supported by the following evidences: (1) Treatment with PPARγ ago-
nist medium-chain triglyceride decanoic acid improved mitochondrial function as evidenced 
by increases in mitochondrial number, activities of mitochondrial enzyme citrate synthase, 
complex I, and catalase [66], whereas treatment with PPARγ agonist rosiglitazone induced 
mitochondrial dysfunction, suggesting rosiglitazone likely induces the mitochondrial dys-
function via PPARγ-independent mechanism [62]. (2) PPARγ-dependent effects are based 
upon altered transcription of genes involved in energy metabolism and usually require hours 
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to days to take into effect. The myocardial energy deficiency was observed after short time 
(30–60 min) exposure to rosiglitazone in our study [62]. Such an acute treatment generally 
does not allow gene expression to change after transcriptional activation of PPARγ, indi-
cating rosiglitazone likely induced myocardial energy deficiency via PPARγ-independent 
mechanism.
To rule out the possibility that rosiglitazone caused myocardial energy deficiency and mito-
chondrial dysfunction through activation of PPARγ in other cardiac cells including fibroblast, 
smooth muscle cells and endothelial cells, we examined the effects of GW9662, a specific 
PPARγ antagonist on the detrimental actions of rosiglitazone on myocardial energy metabo-
lism and mitochondrial function. We found that perfusion of hearts from C57BL/6 mice with 
10 μM GW9662 for 60 min affected neither total ATP content, nor ATP/ADP ratio, nor energy 
charge. This antagonist did not reverse the decreases in total ATP content, ATP/ADP ratio 
and energy charge induced by rosiglitazone at 10 μM in those hearts. Furthermore, 10 μM 
GW9662 showed no effects on the oxidation rates of glucose and palmitate, mitochondrial 
respiration rate, or the activities of mitochondrial complexes I and IV, it did not antagonize 
the downregulations of those parameters by rosiglitazone at the supratherapeutic concentra-
tion of 10 μM, either [62]. Additionally, treatments with rosiglitazone at the supratherapeutic 
concentrations of 10 and 30 μM for 60 min significantly decreased intracellular ATP content 
in cultured mouse cardiomyocytes. In contrast, treatment with 10 μM rosiglitazone showed 
no effect on intracellular ATP content in cultured mouse cardiac fibroblasts, treatment with 
30 μM rosiglitazone only slightly decreased intracellular ATP content in these fibroblasts. 
Interestingly, pretreatment with 30 μM GW9662 did not prevent the decreases in intracellular 
ATP content induced by rosiglitazone in these cultured cardiomyocytes or cardiac fibroblasts 
[62]. These results further support that rosiglitazone induces myocardial energy deficiency 
via PPARγ-independent mechanism.
To maintain energy homeostasis, the capacities of ATP synthesis by mitochondrial oxida-
tive phosphorylation, glycolysis, and phosphotransferase (i.e., creatine kinase, CK) reac-
tions must match the demand for ATP utilization by the sarcomere, ion pumps, etc. [67]. 
Therefore, increased ATP utilization and decreased ATP synthesis, singly or in combination, 
can cause energy deficiency. The free energy of ATP hydrolysis  ∆ GATP decreased follow-
ing rosiglitazone treatment. Furthermore, heart mechanical work (assessed by rate pressure 
product, an indirect index of calcium cycling, metabolic demand, and ATP utilization) also 
decreased following acute treatment with rosiglitazone at 10–30 μM. These results suggest 
that decreased ATP synthesis may be responsible for myocardial energy deficiency induced 
by rosiglitazone. The main pathways for ATP synthesis in hearts are glycolysis, phosphoryl-
transfer reactions, and substrate oxidative phosphorylation. Rosiglitazone showed no effect 
on glycolytic rate-limiting enzymes and the product of CK activity and total creatine content 
[62], indicating that neither glycolysis nor phosphoryltransfer reaction is likely to be involved 
in rosiglitazone-induced myocardial energy deficiency.
The inhibition of complex I by rosiglitazone caused impaired oxidation of NADH and in turn 
decreased NAD content. As a result, NADH/NAD ratio increased. The impaired oxidation of 
NADH leads to decreased substrate oxidation and in turn decreased ATP synthesis. Complex 
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IV acts as the terminus of mitochondrial electron transport by accepting four electrons to 
reduce a single oxygen molecule. The reaction is coupled with the transfer of four protons 
across the mitochondrial membrane, driving ATP synthesis. Thus, the inhibition of both com-
plexes I and IV by rosiglitazone reduces ATP synthesis, which manifests as the myocardial 
energy deficiency induced by rosiglitazone.
5. Rosiglitazone induces myocardial mitochondrial oxidative stress 
via PPARγ-independent mechanism
To assess the in vitro effects of rosiglitazone on redox homeostasis, we determined enzyme 
(NADPH oxidase, xanthine oxidase and mitochondrial complexes I and III)-dependent reac-
tive oxygen species (ROS) O2− production, the capacity of ROS elimination systems including superoxide dismutase (SOD), reduced glutathione (GSH), glutathione peroxidase and catalase, 
and biomarkers malondialdehyde (MDA), protein carbonyl and 8-hydroxy-2’-deoxyguano-
sine (8HOdG) of oxidative damage to lipids, proteins and DNAs, respectively, in isolated 
mitochondria and nuclei. We found that at 1 and 3 μM, rosiglitazone showed no effects on any 
of the aforementioned parameters. At 10 and 30 μM, however, rosiglitazone increased mito-
chondrial complexes I- and III-dependent O2− production, decreased the level of mitochondrial GSH and SOD activity, and increased the levels of mitochondrial MDA, protein carbonyl and 
8-OHdG [62]. Interestingly, pretreatment with 30 μM GW9662 did not prevent rosiglitazone-
induced changes in the above redox parameters. Furthermore, even at the supratherapeutic 
concentrations of 10 and 30 μM, rosiglitazone did not affect the activities of catalase and glu-
tathione peroxidase, and changed neither the level of nuclear protein carbonyl nor the level of 
nuclear 8-OHdG [62]. Similar to our study, rosiglitazone at 50 and 60 μM induced apoptosis 
via oxidative stress in cultured H9c2 cells [68].
We also assessed the acute effects of rosiglitazone on mitochondrial oxidative stress in vivo. 
At 1 mg/kg, injection of rosiglitazone into mouse tail vein showed no effect on the levels of 
myocardial mitochondrial MDA, protein carbonyl and 8-OHdG. At 10 mg/kg, however, rosi-
glitazone increased the levels of these mitochondrial oxidative stress markers. Importantly, 
injection of antioxidant N-acetyl-L-cysteine 600 mg/kg into mouse tail vein prevented the 
above rosiglitazone-induced changes of mitochondrial oxidative stress markers in vivo [62]. 
Furthermore, intravenous injection of GW9662 at 1 mg/kg, previously demonstrated to interact 
selectively with PPARγ, acting as a potent and full PPARγ antagonist, did not prevent 10 mg/kg 
rosiglitazone induced myocardial oxidative stress [62]. Taken together, our in vitro and in vivo 
data support that rosiglitazone induces myocardial mitochondrial oxidative stress via PPARγ-
independent mechanism, possibly by decreasing mitochondrial ROS-scavenging capacity.
6. Rosiglitazone causes cardiac dysfunction via PPARγ-independent 
mechanism
Normal cardiac contractile function requires energy homeostasis. As we found that rosigli-
tazone caused energy deficiency, we therefore further determined the effects of rosiglitazone 
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on cardiac function. In ex vivo Langendorff-perfused hearts, treatment with rosiglitazone at 
1 and 3 μM for 24–30 min showed no obvious effects on cardiac systolic function as assessed 
by left ventricular systolic pressure (LVSP) and the rate of tension development (+dP/dt). 
Treatment with rosiglitazone at 10 and 30 μM for 24–30 min, however, decreased LVSP 
and + dP/dt in hearts from C57BL/6, PPARγ−/− and PPARγ+/+ mice, indicating acute treat-
ment with rosiglitazone at the supratherapeutic concentrations causes cardiac systolic dys-
function [62]. Similarly, treatment with rosiglitazone at 1 and 3 μM for 24–30 min showed no 
obvious effects on cardiac diastolic function as assessed by left ventricular end diastolic pres-
sure (EDP) and the rate of relaxation (–dP/dt). Treatment with rosiglitazone at 10 and 30 μM 
for 24–30 min, however, increased EDP and decreased –dP/dt in all hearts from the above 
three genotypes, indicating acute treatment with rosiglitazone at the supratherapeutic con-
centrations also causes cardiac diastolic dysfunction [62]. Interestingly, rosiglitazone-induced 
cardiac dysfunction was not distinguishable among C57BL/6, PPARγ−/− and PPARγ+/+ mice, 
indicating acute rosiglitazone treatment caused cardiac dysfunction independently of car-
diomyocyte PPARγ [62]. Additionally, treatment of hearts with 10 μM GW9662 for 60 min, 
affected neither cardiac function, nor rosiglitazone-induced cardiac dysfunction. In contrast, 
treatment of hearts with 20 mM N-acetyl-L-cysteine (NAC) for 60 min did not affect baseline 
cardiac function, but prevented cardiac dysfunction induced by rosiglitazone at the suprath-
erapeutic concentration of 10 μM [62]. These data further support that rosiglitazone induced 
cardiac dysfunction via a mechanism related to oxidative stress and independent of PPARγ.
We also evaluated the side effects of rosiglitazone on cardiac function in vivo setting by 
using echocardiography. Injection of rosiglitazone at the dose of 1 mg/kg into mouse tail vein 
showed no effect on cardiac function as assessed by fraction shorting [29] and ejection fraction 
EF). At 10 mg/kg, however, rosiglitazone decreased FS and EF, indicating rosiglitazone caused 
cardiac dysfunction at a higher dose. NAC at 600 mg/kg alone showed no effect on cardiac 
function. In combination with 10 mg/kg rosiglitazone, however, this antioxidant prevented 
rosiglitazone-induced cardiac dysfunction. In contrast, intravenous injection of PPARγ selec-
tive antagonist GW9662 at 1 mg/kg did not prevent 10 mg/kg rosiglitazone-induced cardiac 
dysfunction [62]. These in vivo studies also support that rosiglitazone induces cardiac dys-
function via a mechanism related to oxidative stress and independent of PPARγ.
7. TZDs induce cardiac hypertrophy via PPARγ-independent 
mechanism
TZDs are expected to inhibit cardiomyocyte growth in vitro and in pressure overload mod-
els via activation of PPARγ. Paradoxically, TZDs have also been reported to induce cardiac 
hypertrophy in mice, rats and dogs [69, 70]. This side effect may occur because TZDs expand 
blood volume. However, an essential question is whether or not this effect is directly attribut-
able to cardiac PPARγ activation. Treatment with TZD rosiglitazone 10 mg/kg per day for 
4 weeks induced cardiac hypertrophy in both PPARγ−/− and PPARγ+/+ mice. Rosiglitazone 
treatment increased cardiac phosphorylation of p38 mitogen-activated protein kinase (p38-
MAPK), a MAPK pathway essential for cardiac hypertrophy, in PPARγ−/− mice. The effect 
of rosiglitazone on p38-MAPK persisted in PPARγ−/− mouse hearts indicated that activation 
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of p38-MAPK by TZDs is independent of cardiomyocyte PPARγ [70]. Furthermore, phos-
phorylation of c-Jun N-terminal kinases was not affected by rosiglitazone or cardiomyocyte 
PPARγ deletion. Surprisingly, despite hypertrophy, AKT phosphorylation was suppressed in 
PPARγ−/− mouse hearts [70]. These data demonstrate that cardiomyocyte PPARγ suppresses 
cardiac growth and embryonic gene expression and inhibits nuclear factor κB activity in vivo, 
and that rosiglitazone causes cardiac hypertrophy at least partially independent of PPAR-γ 
in cardiomyocytes [70].
8. TZDs increase risks of heart failure
Congestive heart failure (CHF) is a major complication of diabetes and occurs as a result 
of both atherosclerotic coronary disease and non-ischemic diabetic cardiomyopathy. TZDs 
improve glycemic control and afford beneficial effects on many markers of cardiovascular 
risk including blood pressure, waist to hip ratio, HDL levels, endothelial reactivity, C-reactive 
protein, fibrinolysis, and microalbuminuria by improving peripheral insulin sensitivity. These 
antidiabetic agents, however, have been reported to worsen the existing CHF or precipitate 
new-onset failure in several reviews and meta-analyses of placebo-controlled randomized 
clinical trials (RCTs).
Bolen et al. found that the risk for CHF was higher with TZDs as either monotherapy or com-
bination therapy than with metformin or sulfonylureas, with a range of 0.8–3.6% for TZDS 
and 0–2.6% for non-TZDs [4]. Lago et al. found an increased risk of CHF in use of TZDs in 
patients with diabetes and prediabetes compared with placebo and active-controls: relative 
risk 1.72, 95% confidence interval (CI) 1.21–2.42. The overall event rate for CHF with TZDs 
was 2.3% and with the comparison drugs 1.4% [14]. Singh et al. reported that the relative 
risk of CHF in use of rosiglitazone in patients with diabetes or prediabetes compared with 
various other antidiabetic drugs was 2.09 (95% CI 1.52–2.88) [17]. They also examined onset 
of CHF in both pioglitazone and rosiglitazone compared with placebo in three randomized 
controlled trials with subjects with either type 2 diabetes or prediabetes. The odds ratio (OR) 
for all heart failure adverse events was 2.10 (95% CI 1.08–4.08). Four observational studies 
produced an OR 1.55 (95% CI 1.33–1.80). These authors also examined case reports, including 
162 case subjects with 99 analyzable cases. Among these cases, the median time to onset of 
CHF was 24 weeks, although failure could occur early and did not appear to relate to dosage. 
CHF was not limited to the elderly; 26% of cases were in subjects less than 60 years of age [71]. 
Hernandez et al. found that the TZD therapy was significantly and consistently associated 
with a higher risk of CHF: TZDs 360/6807 [5.3%] versus placebo 234/6328 [3.7%], OR 1.59; 
95% CI 1.34–1.89; p < 0.00001. The risk of CHF was higher with rosiglitazone than with piogli-
tazone (OR 2.73; 95% CI 1.46–5.10) versus (OR 1.51; 95% CI 1.26–1.81; p = 0.06). Rosiglitazone 
and pioglitazone were associated with a similar risk of serious/severe CHF (OR 1.47; 95% 
CI 1.16–1.87; p = 0.002). The use of TZDs was also associated with edema (OR 2.04; 95% CI 
1.85–2.26; p < 0.00001) [72]. The above increased risk of CHF was largely confirmed in other 
meta-analyses: the use of rosiglitazone for >4 weeks in 132 trials involving 41,743 patients 
with or without T2DM was associated with a 69% higher relative risk of serious CHF [73]; and 
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the combined short- and long-term use of pioglitazone in 19 RCTs involving 16,390 patients 
with T2DM found a 41% higher relative risk of serious CHF [74]. Another meta-analysis of 26 
RCTs found 126% higher odds of peripheral edema in 15,332 diabetics with short- and long-
term use of TZDs [75].
One of the potential mechanisms responsible for increased risk in CHF with TZD treatment 
may be the fluid accumulation observed in large-scale studies on antidiabetic medications 
[74–76]. In spite of a weak beneficial effect on blood pressure [77], volume overload beyond 
a certain threshold induced by TZDs increases the myocardial energy demand of the left 
ventricular and triggers metabolic disorder. As a compensatory mechanism, the contractile 
function of myocardia is temporarily restored via cardiac hypertrophy, overtaking the grow-
ing amount of mitochondrial respiration and ATP production gradually.
In susceptible individuals, these pathophysiological responses likely explain why rosi-
glitazone precipitate clinical heart failure, and why ischemic events are easily provoked. 
Notably, the sodium-retentive actions of rosiglitazone within the renal tubules are dose and 
duration-dependent and insulin-independent, accordingly, it is likely that concurrent treat-
ment with insulin and rosiglitazone mutually reinforces the risk of each agent, thus mark-
edly increases the possibility of worsening heart failure. The reasons for fluid retention and 
peripheral edema with TZD use are not fully understood and are likely to be multifactorial. 
One possibility is the reduction in renal excretion of sodium and an increase in sodium and 
free water retention. Whether these actions are PPARγ-dependent or not warrants further 
study.
The other potential mechanism responsible for increased risk in CHF with TZDs treatment 
may be related to their direct adverse effects on myocardial energy deficiency, mitochon-
drial function and cardiac function observed in our previous study [62]. It is well known 
that altered energy metabolism and cardiac dysfunction are common features of heart fail-
ure resulted from different causes, including diabetes. We demonstrated that rosiglitazone 
induced myocardial energy deficiency, mitochondrial dysfunction and cardiac dysfunction in 
perfused mouse hearts at the supratherapeutic concentrations of 10 and 30 μM and induced 
cardiac dysfunction in vivo at a high dose of 10 mg/kg [62]. TZDs might be accumulated over 
a longer period of time in the cell or their effects are in some other way “cumulative” in some 
patients who need increased doses due to the tolerance during a long period of therapeutic 
time, and in diabetic patients with renal dysfunction. Therefore, it is likely that TZDs increase 
the risk of heart failure in T2DM patients through their PPARγ-independent adverse effects 
on the heart.
9. TZDs increase risks of myocardial infarction
Muraglitazar, an investigational dual PPARα and PPARγ agonist, was the first TZD agent 
halted because of increased adverse cardiovascular events, including myocardial infarction, 
transient ischemic attack, and stroke, during phase 2 and 3 trials [78]. In 2007, Nissen and 
Wolski performed the first large meta-analysis of 42 trials involving 27,847 patients with 
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randomized control group not receiving rosiglitazone and found that rosiglitazone was 
associated with a significant increase in the risk of myocardial infarction (OR 1.43, 95% CI 
1.03–1.98, P = 0.03) and with an increase in the risk of cardiovascular death (OR 1.64, 95% 
CI 0.98–2.74, P = 0.06) [16]. In 2010, Nissen and Wolski published an update including 56 
trials with 35,531 randomized patients: 19,509 who received rosiglitazone and 16,022 who 
received control therapy. They continued to demonstrate that rosiglitazone therapy signifi-
cantly increased the risk of myocardial infarction (OR 1.28, 95% CI 1.02–1.63, P = 0.04) [79]. 
Consistent with above analyses, Ontario study [80] and Taiwan study [81] also reported the 
increased risks in both myocardial infarction and cardiovascular death following the treat-
ment with rosiglitazone. Several other meta-analyses by Psaty and Furberg, GlaxoSmithKline, 
U.S. FDA and Singh et al. found the increased risks in myocardial infarction but uncertainty 
in cardiovascular death in patients with rosiglitazone treatment [17, 82, 83], whereas meta-
analysis by Shuster et al. reported the increased risk in cardiovascular death but uncertainty 
in myocardial infarction in subjects treated with rosiglitazone [84].
In contrast, the meta-analysis by Diamond et al. and Lago et al. reported that rosiglitazone 
was not associated with an increase in the risk of myocardial infarction and cardiovascular 
death [14, 85].
These discrepancies can be ascribed to the inconsistencies in trial design, eligibility, fol-
low-up, sample size, analytical methodology, and endpoint criteria among analyses and 
studies.
The mechanisms responsible for increased risks in myocardial infarction and cardiovascular 
death related to TZDs are not fully characterized. Several contributing factors are possible: first, 
the reduction in hemoglobin. TZDs, including rosiglitazone, may produce a modest reduc-
tion in the hemoglobin level. In susceptible patients, a reduced hemoglobin level may result 
in increased physiological stress, thereby provoking myocardial ischemia [16]. The second is 
adverse effects on serum lipids. TZDs may produce detrimental influences on serum lipids. 
Rosiglitazone increased low-density lipoprotein cholesterol (LDL-C) concentration of 18.6% 
among T2DM patients treated for 26 weeks with an 8-mg daily dose via increasing serum 
paraoxonase activity, which protects LDL-C against lipid peroxidation. This TZD also signifi-
cantly increased triglyceride levels in 50 patients who were given at 4 mg/day for 3 months in 
addition to their usual treatment compared to baseline levels [86, 87]. Higher LDL-C level was 
consistently and independently associated with higher incidences of major adverse cardiovas-
cular events after controlling for conventional risk factors [88]. Third, overload of intravascular 
volume. TZDs may induce fluid retention and peripheral edema likely via the reduction in 
renal excretion of sodium and an increase in sodium and free water retention [13]. The volume 
overload increases stress on the left ventricular wall, a factor that determines myocardial oxy-
gen demand. In susceptible patients, an increase in myocardial oxygen demand could theoreti-
cally provoke ischemic events.
10. Summary
There are two TZDs approved for prescription use in the United States: rosiglitazone male-
ate (Avandia) and pioglitazone hydrochloride (Actos). Both have been widely used to treat 
adult patients with T2DM, either as monotherapy or in combination with insulin, metformin, 
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or sulfonylurea when diet, exercise, and a single agent does not result in adequate glycemic 
control. The mechanisms of action of TZDs in lowering plasma glucose among patients with 
T2DM are thought to include the following: increase insulin sensitivity, decrease endog-
enous glucose production and postprandial gluconeogenesis, increase fasting and postpran-
dial glucose clearance, and have beneficial effects on beta-cell function. The glycemic effects 
of these agents are thought to be mediated by binding to PPARγ (Figure 1).
Their efficacy and beneficial effects, however, are shadowed by the increased risks of cardio-
vascular adverse events. Evidences are accumulating that TZDs, particularly rosiglitazone, 
cause cardiotoxicity including myocardial energy deficiency, mitochondrial dysfunction, 
and oxidative stress with concomitant cardiac dysfunction in ex vivo perfused hearts. TZDs 
may also cause cardiac hypertrophy in whole animal model. Additionally, TZDs increase 
the risks of heart failure and myocardial infarction in patients with T2DM. Understanding 
whether the cardiotoxicity induced by TZDs is PPARγ independent or not is an important 
issue for designing more specific PPARγ agonists with fewer side effects. TZDs also have 
affinity to numerous non-PPARγ targets in mitochondria, cytosol and cytoplasm, including 
Figure 1. PPARγ-dependent (on-target) and -independent (off-target) effects of thiazolidinediones (TZDs). TZDs produce 
on-target effects by binding to nucleus PPARγ, increasing insulin sensitivity and glucose oxidation and contributing 
to efficacy of the drugs. They produce off-target effects by binding to numerous non-PPARγ targets including 
MitoNEET, mitochondrial pyruvate carrier (MCP), dehydrogenases involved in TCA cycle and electron transport chain 
complexes, cytoplasmic ion channels, Na-K-pump and other unknown enzymes. Off-target effects potentially increase 
cardiotoxicity including mitochondrial (Mito) dysfunction, oxidative stress and myocardial energy deficiency, fluid 
retention, congestive heart failure and myocardial infarction. Paradoxically, Mito dysfunction and energy deficiency 
may also stimulate insulin sensitivity and glucose uptake in the heart and indirectly contributing to efficacy of the drugs. 
A-CoA, acetyl-coenzyme A; TCA, tricarboxylic acid; e−, electron; CI, CII, CIII, CIV and CV, mitochondrial respiratory 
chain complexes I, II, III, IV and V, respectively; Q, coenzyme Q.
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MitoNEET, mitochondrial pyruvate carrier (MCP), dehydrogenases involved in TCA cycle 
and electron transport, cytoplasmic ion channels, Na-K-pump and other unknown enzymes. 
By binding to these non-PPARγ targets, TZDs produce off-target effects and potentially 
increase cardiotoxicity including mitochondrial dysfunction, oxidative stress and myo-
cardial energy deficiency, fluid retention, congestive heart failure and myocardial infarc-
tion. Paradoxically, mitochondrial dysfunction and energy deficiency may also stimulate 
insulin sensitivity and glucose uptake in the heart and indirectly contributing to efficacy of 
TZDs. Therefore, TZDs may produce antidiabetic effects via both PPARγ-dependent and 
PPARγ-independent mechanisms, and they may induce cardiotoxicity solely via PPARγ-
independent mechanism (Figure 1). This chapter also raised concerns that the use of TZDs 
may lead to a significant increase in adverse cardiovascular effects. The benefit/risk profile 
of TZDs should be considered when treating diabetic patients with or without prior cardio-
vascular diseases.
Acknowledgements
This work was partially supported by the National Institutes of Health [R01 HL46033 and 
HL78634 to JAB, P50 HL074734 to FXM, and by Brigham and Women’s Fund 104401 to HH.
Conflict of interest
Authors declare no conflict of interest.
Author details
Jing-Bo Jiang1, James A. Balschi2, Francis X. McGowan Jr 3 and Huamei He2*
*Address all correspondence to: hhe3@bwh.harvard.edu
1 Department of Neonatology, Shenzhen Children’s Hospital, Shenzhen, China
2 Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 
Boston, Massachusetts, USA
3 Department of Anesthesiology and Critical Care Medicine, Children’s Hospital of 
Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, USA
References
[1] Horita S, Nakamura M, Satoh N, Suzuki M, Seki G. Thiazolidinediones and edema: 
Recent advances in the pathogenesis of thiazolidinediones-induced renal sodium reten-
tion. PPAR Research. 2015;2015:646423
Cardiotoxicity82
[2] Day C. Thiazolidinediones: A new class of antidiabetic drugs. Diabetic Medicine. 1999; 
16(3):179-192
[3] Vasudevan AR, Balasubramanyam A. Thiazolidinediones: A review of their mechanisms 
of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes 
Technology & Therapeutics. 2004;6(6):850-863
[4] Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic review: 
Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. 
Annals of Internal Medicine. 2007;147(6):386-399
[5] Ishida H, Takizawa M, Ozawa S, Nakamichi Y, Yamaguchi S, Katsuta H, et al. Pioglitazone 
improves insulin secretory capacity and prevents the loss of beta-cell mass in obese dia-
betic db/db mice: Possible protection of beta cells from oxidative stress. Metabolism. 
2004;53(4):488-494
[6] Zeender E, Maedler K, Bosco D, Berney T, Donath MY, Halban PA. Pioglitazone and 
sodium salicylate protect human beta-cells against apoptosis and impaired function 
induced by glucose and interleukin-1beta. The Journal of Clinical Endocrinology and 
Metabolism. 2004;89(10):5059-5066
[7] Campbell IW, Mariz S. Beta-cell preservation with thiazolidinediones. Diabetes Research 
and Clinical Practice. 2007;76(2):163-176
[8] Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic 
durability of rosiglitazone, metformin, or glyburide monotherapy. The New England 
Journal of Medicine. 2006;355(23):2427-2443
[9] Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. PPARgamma sig-
naling and metabolism: The good, the bad and the future. Nature Medicine. 2013;19(5): 
557-566
[10] Laakso M. Cardiovascular disease in type 2 diabetes: Challenge for treatment and pre-
vention. Journal of Internal Medicine. 2001 Mar;249(3):225-235
[11] Levitt Katz L, Gidding SS, Bacha F, Hirst K, McKay S, Pyle L, et al. Alterations in left 
ventricular, left atrial, and right ventricular structure and function to cardiovascular 
risk factors in adolescents with type 2 diabetes participating in the TODAY clinical trial. 
Pediatric Diabetes. 2015;16(1):39-47
[12] Rosano GM, Vitale C, Seferovic P. Heart failure in patients with diabetes mellitus. 
Cardiac Failure Review. 2017;3(1):52-55
[13] Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione 
use, fluid retention, and congestive heart failure: A consensus statement from the American 
Heart Association and American Diabetes Association. Circulation. 2003;108(23):2941- 
2948
[14] Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in 
patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis 
of randomised clinical trials. Lancet. 2007;370(9593):1129-1136
Thiazolidinediones Cause Cardiotoxicity via PPARγ-Independent Mechanism
http://dx.doi.org/10.5772/intechopen.78957
83
[15] Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, et al. Rosiglitazone 
evaluated for cardiovascular outcomes—An interim analysis. The New England Journal 
of Medicine. 2007;357(1):28-38
[16] Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction 
and death from cardiovascular causes. The New England Journal of Medicine. 
2007;356(24):2457-2471
[17] Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: 
A meta-analysis. Journal of the American Medical Association. 2007;298(10):1189-1195
[18] Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai 
B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovas-
cular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised 
controlled trials. BMJ. 2011;343:244
[19] Greene SJ, Vaduganathan M, Khan MS, Bakris GL, Weir MR, Seltzer JH, et al. Prevalent 
and incident heart failure in cardiovascular outcome trials of patients with type 2 diabe-
tes. Journal of the American College of Cardiology. 2018;71(12):1379-1390
[20] Krentz A. Thiazolidinediones: Effects on the development and progression of type 2 
diabetes and associated vascular complications. Diabetes/Metabolism Research and 
Reviews. 2009;25(2):112-126
[21] Liao HW, Saver JL, Wu YL, Chen TH, Lee M, Ovbiagele B. Pioglitazone and cardiovas-
cular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: A 
systematic review and meta-analysis. BMJ Open. 2017;7(1):e013927
[22] Berger J, Moller DE. The mechanisms of action of PPARs. Annual Review of Medicine. 
2002;53:409-435
[23] Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 
2000;405(6785):421-424
[24] Grygiel-Gorniak B. Peroxisome proliferator-activated receptors and their ligands: 
Nutritional and clinical implications—A review. Nutrition Journal. 2014;13:17
[25] Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxi-
some proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, −beta, 
and -gamma in the adult rat. Endocrinology. 1996 Jan;137(1):354-366
[26] Monsalve FA, Pyarasani RD, Delgado-Lopez F, Moore-Carrasco R. Peroxisome prolif-
erator-activated receptor targets for the treatment of metabolic diseases. Mediators of 
Inflammation. 2013;2013:549627
[27] Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. 
Trends in Cardiovascular Medicine. 2000;10(6):238-245
[28] Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, et al. 
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. 
Pharmacological Reviews. 2006;58(4):726-741
Cardiotoxicity84
[29] Jonker JW, Suh JM, Atkins AR, Ahmadian M, Li P, Whyte J, et al. A PPARgamma-FGF1 
axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature. 
2012;485(7398):391-394
[30] Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: Nuclear control of 
metabolism. Endocrine Reviews. 1999;20(5):649-688
[31] Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. Coordinate regulation 
of the expression of the fatty acid transport protein and acyl-CoA synthetase genes 
by PPARalpha and PPARgamma activators. The Journal of Biological Chemistry. 
1997;272(45):28210-28217
[32] Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM. PPAR gamma 2 regulates 
adipose expression of the phosphoenolpyruvate carboxykinase gene. Molecular and 
Cellular Biology.1995;15(1):351-357
[33] Baumann CA, Chokshi N, Saltiel AR, Ribon V. Cloning and characterization of a func-
tional peroxisome proliferator activator receptor-gamma-responsive element in the pro-
moter of the CAP gene. Journal of Biological Chemistry. 2000;275(13):9131-9135
[34] Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N. Expression of putative fatty 
acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha 
and gamma activators in a tissue- and inducer-specific manner. The Journal of Biological 
Chemistry. 1998;273(27):16710-16714
[35] Kim HI, Cha JY, Kim SY, Kim JW, Roh KJ, Seong JK, et al. Peroxisomal proliferator-acti-
vated receptor-gamma upregulates glucokinase gene expression in beta-cells. Diabetes. 
2002;51(3):676-685
[36] Kim SY, Kim HI, Park SK, Im SS, Li T, Cheon HG, et al. Liver glucokinase can be acti-
vated by peroxisome proliferator-activated receptor-gamma. Diabetes. 2004;53(Suppl 1): 
S66-S70
[37] Wu Z, Xie Y, Morrison RF, Bucher NL, Farmer SR. PPARgamma induces the insulin-
dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the 
conversion of 3T3 fibroblasts into adipocytes. The Journal of Clinical Investigation. 
1998;101(1):22-32
[38] Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA. A futile metabolic cycle 
activated in adipocytes by antidiabetic agents. Nature Medicine. 2002;8(10):1122-1128
[39] Lasar D, Rosenwald M, Kiehlmann E, Balaz M, Tall B, Opitz L, et al. Peroxisome prolif-
erator activated receptor gamma controls mature brown adipocyte inducibility through 
glycerol kinase. Cell Reports. 2018 Jan 16;22(3):760-773
[40] Smith U, Gogg S, Johansson A, Olausson T, Rotter V, Svalstedt B. Thiazolidinediones 
(PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 
3T3-L1 and human adipocytes. The FASEB Journal. 2001 Jan;15(1):215-220
[41] Sigrist S, Bedoucha M, Boelsterli UA. Down-regulation by troglitazone of hepatic tumor 
necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-
insulin-dependent diabetes. Biochemical Pharmacology. 2000;60(1):67-75
Thiazolidinediones Cause Cardiotoxicity via PPARγ-Independent Mechanism
http://dx.doi.org/10.5772/intechopen.78957
85
[42] Saraf N, Sharma PK, Mondal SC, Garg VK, Singh AK. Role of PPARg2 transcription 
factor in thiazolidinedione-induced insulin sensitization. The Journal of Pharmacy and 
Pharmacology. 2012;64(2):161-171
[43] Kallen CB, Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (Ob) gene expres-
sion in 3T3-L1 adipocytes. Proceedings of the National Academy of Sciences of the 
United States of America. 1996;93(12):5793-5796
[44] Toruner F, Akbay E, Cakir N, Sancak B, Elbeg S, Taneri F, et al. Effects of PPARgamma 
and PPARalpha agonists on serum leptin levels in diet-induced obese rats. Hormone 
and Metabolic Research. 2004;36(4):226-230
[45] Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, 
et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific tran-
scriptional response via a PPRE in the lipoprotein lipase gene. The EMBO Journal. 
1996;15(19):5336-5348
[46] Gervois P, Torra IP, Fruchart JC, Staels B. Regulation of lipid and lipoprotein metabo-
lism by PPAR activators. Clinical Chemistry and Laboratory Medicine. 2000;38(1):3-11
[47] Dalen KT, Schoonjans K, Ulven SM, Weedon-Fekjaer MS, Bentzen TG, Koutnikova 
H, et al. Adipose tissue expression of the lipid droplet-associating proteins S3-12 and 
perilipin is controlled by peroxisome proliferator-activated receptor-gamma. Diabetes. 
2004;53(5):1243-1252
[48] Kim HJ, Jung TW, Kang ES, Kim DJ, Ahn CW, Lee KW, et al. Depot-specific regulation 
of perilipin by rosiglitazone in a diabetic animal model. Metabolism. 2007;56(5):676-85
[49] Devine JH, Eubank DW, Clouthier DE, Tontonoz P, Spiegelman BM, Hammer RE, et al. 
Adipose expression of the phosphoenolpyruvate carboxykinase promoter requires 
peroxisome proliferator-activated receptor gamma and 9-cis-retinoic acid receptor 
binding to an adipocyte-specific enhancer in vivo. The Journal of Biological Chemistry. 
1999;274(19):13604-13612
[50] Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A. Rosigli 
tazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-
terminal kinase/activating protein 1 pathway and protects the heart from ischemia/
reperfusion injury. Diabetes. 2002;51(5):1507-1514
[51] Morrison A, Yan X, Tong C, Li J. Acute rosiglitazone treatment is cardioprotective 
against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in 
nondiabetic mice. American Journal of Physiology. Heart and Circulatory Physiology. 
2011 Sep;301(3):H895-H902
[52] Zhu P, Lu L, Xu Y, Schwartz GG. Troglitazone improves recovery of left ventricular func-
tion after regional ischemia in pigs. Circulation. 2000;101(10):1165-1171
[53] Xu Y, Gen M, Lu L, Fox J, Weiss SO, Brown RD, et al. PPAR-gamma activation fails to 
provide myocardial protection in ischemia and reperfusion in pigs. American Journal of 
Physiology. Heart and Circulatory Physiology. 2005;288(3):H1314-H1323
Cardiotoxicity86
[54] Colca JR, McDonald WG, Waldon DJ, Leone JW, Lull JM, Bannow CA, et al. Identification 
of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidin-
edione photoprobe. American Journal of Physiology. Endocrinology and Metabolism. 
2004;286(2):E252-E260
[55] Wiley SE, Murphy AN, Ross SA, van der Geer P, Dixon JE. MitoNEET is an iron-
containing outer mitochondrial membrane protein that regulates oxidative capacity. 
Proceedings of the National Academy of Sciences of the United States of America. 
2007;104(13):5318-5323
[56] Zuris JA, Harir Y, Conlan AR, Shvartsman M, Michaeli D, Tamir S, et al. Facile transfer 
of [2Fe-2S] clusters from the diabetes drug target mitoNEET to an apo-acceptor pro-
tein. Proceedings of the National Academy of Sciences of the United States of America. 
2011;108(32):13047-13052
[57] Kusminski CM, Holland WL, Sun K, Park J, Spurgin SB, Lin Y, et al. MitoNEET-driven 
alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that pre-
serves insulin sensitivity in obesity. Nature Medicine. 2012;18(10):1539-1549
[58] Paddock ML, Wiley SE, Axelrod HL, Cohen AE, Roy M, Abresch EC, et al. MitoNEET 
is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pio-
glitazone. Proceedings of the National Academy of Sciences of the United States of 
America. 2007;104(36):14342-14347
[59] Colca JR, McDonald WG, Cavey GS, Cole SL, Holewa DD, Brightwell-Conrad AS, 
et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers 
(mTOT)—Relationship to newly identified mitochondrial pyruvate carrier proteins. 
PLoS One. 2013;8(5):e61551
[60] Colca JR, VanderLugt JT, Adams WJ, Shashlo A, McDonald WG, Liang J, et al. Clinical 
proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensi-
tizer. Clinical Pharmacology and Therapeutics. 2013;93(4):352-359
[61] Hoffmann BR, El-Mansy MF, Sem DS, Greene AS. Chemical proteomics-based analy-
sis of off-target binding profiles for rosiglitazone and pioglitazone: Clues for assessing 
potential for cardiotoxicity. Journal of Medicinal Chemistry. 2012;55(19):8260-8271
[62] He H, Tao H, Xiong H, Duan SZ, McGowan FX Jr, Mortensen RM, et al. Rosiglitazone 
causes cardiotoxicity via peroxisome proliferator-activated receptor gamma-inde-
pendent mitochondrial oxidative stress in mouse hearts. Toxicological Sciences. 
2014;138(2):468-481
[63] Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, et al. Thiazolidinediones, 
like metformin, inhibit respiratory complex I: A common mechanism contributing to 
their antidiabetic actions? Diabetes. 2004;53(4):1052-1059
[64] Rachek LI, Yuzefovych LV, Ledoux SP, Julie NL, Wilson GL. Troglitazone, but not rosigl-
itazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell 
death in human hepatocytes. Toxicology and Applied Pharmacology. 2009;240(3):348-354
Thiazolidinediones Cause Cardiotoxicity via PPARγ-Independent Mechanism
http://dx.doi.org/10.5772/intechopen.78957
87
[65] Scatena R, Bottoni P, Martorana GE, Ferrari F, De Sole P, Rossi C, et al. Mitochondrial 
respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-
ligands: Biochemical and pharmacological implications. Biochemical and Biophysical 
Research Communications. 2004;319(3):967-973
[66] Hughes SD, Kanabus M, Anderson G, Hargreaves IP, Rutherford T, O'Donnell M, et al. 
The ketogenic diet component decanoic acid increases mitochondrial citrate synthase 
and complex I activity in neuronal cells. Journal of Neurochemistry. 2014;129(3):426-433
[67] Ingwall JS. On the control of metabolic remodeling in mitochondria of the failing heart. 
Circulation. Heart Failure. 2009;2(4):275-277
[68] Mishra P, Singh SV, Verma AK, Srivastava P, Sultana S, Rath SK. Rosiglitazone induces 
cardiotoxicity by accelerated apoptosis. Cardiovascular Toxicology 2014;14(2):99-119
[69] Arakawa K, Ishihara T, Aoto M, Inamasu M, Kitamura K, Saito A. An antidiabetic thia-
zolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats. 
Clinical and Experimental Pharmacology & Physiology. 2004;31(1-2):8-13
[70] Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM. Cardiomyocyte-
specific knockout and agonist of peroxisome proliferator-activated receptor-gamma 
both induce cardiac hypertrophy in mice. Circulation Research. 2005;97(4):372-379
[71] Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: A teleo-analysis. 
Diabetes Care. 2007;30(8):2148-2153
[72] Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of 
heart failure in patients with or at high risk of type 2 diabetes mellitus: A meta-analysis 
and meta-regression analysis of placebo-controlled randomized clinical trials. American 
Journal of Cardiovascular Drugs. 2011;11(2):115-128
[73] Mannucci E, Monami M, Di Bari M, Lamanna C, Gori F, Gensini GF, et al. Cardiac safety 
profile of rosiglitazone: A comprehensive meta-analysis of randomized clinical trials. 
International Journal of Cardiology. 2010;143(2):135-140
[74] Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular 
events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. 
Journal of the American Medical Association. 2007;298(10):1180-1188
[75] Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: A meta-analy-
sis. Diabetes Research and Clinical Practice. 2007;76(2):279-289
[76] Lu Y, Ma D, Xu W, Shao S, Yu X. Effect and cardiovascular safety of adding rosiglitazone 
to insulin therapy in type 2 diabetes: A meta-analysis. Journal of Diabetes Investigation. 
2015;6(1):78-86
[77] Sarafidis PA, Nilsson PM. The effects of thiazolidinediones on blood pressure levels—A 
systematic review. Blood Pressure. 2006;15(3):135-150
[78] Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse car-
diovascular events in patients with type 2 diabetes mellitus. Journal of the American 
Medical Association. 2005;294(20):2581-2586
Cardiotoxicity88
[79] Nissen SE, Wolski K. Rosiglitazone revisited: An updated meta-analysis of risk for 
myocardial infarction and cardiovascular mortality. Archives of Internal Medicine. 
2010;170(14):1191-1201
[80] Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones 
and cardiovascular outcomes in older patients with diabetes. Journal of the American 
Medical Association. 2007;298(22):2634-2643
[81] Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW. Thiazolidinediones and 
cardiovascular events in patients with type 2 diabetes mellitus: A retrospective cohort 
study of over 473,000 patients using the National Health Insurance database in Taiwan. 
Drug Safety. 2009;32(8):675-690
[82] Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardial infarc-
tion. The New England Journal of Medicine. 2007;357(1):67-69
[83] Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH. Thiazolidinedione Drugs 
and Cardiovascular Risks: A science advisory from the American Heart Association and 
American College of Cardiology Foundation. Circulation. 2010;121(16):1868-1877
[84] Shuster JJ, Jones LS, Salmon DA. Fixed vs random effects meta-analysis in rare event 
studies: The rosiglitazone link with myocardial infarction and cardiac death. Statistics in 
Medicine. 2007;26(24):4375-4385
[85] Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial 
infarction and cardiovascular death. Annals of Internal Medicine. 2007;147(8):578-581
[86] Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison 
of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 
diabetes and dyslipidemia. Diabetes Care. 2005;28(7):1547-1554
[87] Atamer Y, Atamer A, Can AS, Hekimoglu A, Ilhan N, Yenice N, et al. Effects of rosigli-
tazone on serum paraoxonase activity and metabolic parameters in patients with type 2 
diabetes mellitus. Brazilian Journal of Medical and Biological Research. 2013;46(6):528-532
[88] Shiiba M, Zhang B, Miura SI, Ike A, Nose D, Kuwano T, et al. Association between dis-
cordance of LDL-C and non-HDL-C and clinical outcomes in patients with stent implan-
tation: From the FU-Registry. Heart and Vessels. 2018;33(2):102-112
Thiazolidinediones Cause Cardiotoxicity via PPARγ-Independent Mechanism
http://dx.doi.org/10.5772/intechopen.78957
89

